Distribution of Rifampicin-Resistant Tuberculosis Patients based on Presumptive Drug-Resistant Tuberculosis Criteria at Dr. Hasan Sadikin Hospital 2016–2019

Dinda Nursyafira Misyatin, Arto Yuwono Soeroto, Ferdy Ferdian


Background: Diagnosis of drug-resistant tuberculosis (DR-TB) begins with identifying presumptive DR-TB patients using Xpert MTB/RIF, as a diagnostic test to detect resistance to rifampicin. The study aimed to identify the distribution of rifampicin-resistant tuberculosis (RR-TB) patients based on presumptive DR-TB criteria at Dr. Hasan Sadikin General Hospital Bandung. Moreover, this study also explored the Xpert MTB/RIF Ct values.

Methods: This was a descriptive-retrospective study from 570 medical records of DR-TB patients collected at the Multidrug-resistant tuberculosis (MDR-TB) clinic of Dr. Hasan Sadikin General Hospital from 2016 to 2019. The inclusion criteria were suspected patients with the Xpert MTB/RIF Ct values in the very low-low and medium-high categories. Data were analyzed using frequency distribution.

Results: The most common presumptive DR-TB criteria among DR-TB patients were relapse cases (52.3%). Presumptive DR-TB criteria, with a high percentage result of medium-high Ct values, were category II treatment failure (80.9%).

Conclusion: Relapse case and category II treatment failure are presumptive DR-TB criteria, which need more attention from clinicians.


Presumptive DR-TB criteria, tuberculosis, Xpert MTB/RIF Ct values

Full Text:



  1. World Health Organization. Global tuberculosis report. Geneva, Switzerland: WHO; 2019.
  2. Management Sciences for Health. e-TB manager: report TB06 [internet]. [Cited 2020 October 13]. Available from: etbmanager.sitb.id
  3. Ministry of Health Republic of Indonesia. Minister of Health Decree No. 67/2016 about Tuberculosis Control. Jakarta: Ministry of Health Republic of Indonesia; 2016.
  4. Fradejas I, OntañónB, Muñoz-gallegoI, Ramirez-Vela MJ, López-Roa P. The value of xpert MTB/RIF-generated CT values for predicting the smear status of patients with pulmonary tuberculosis. J Clin Tuberc Other Mycobact Dis. 2018;13:9–12.
  5. Sabiiti W, Azam K, Farmer ECM, Kuchaka D, Mtafya B, Bowness R, et al. Tuberculosis bacillary load, an early marker of disease severity: the utility of tuberculosis molecular bacterial load assay. Thorax. 2020;75:606–8.
  6. van Kampen SC, Susanto NH, Simon S, Astiti SD, Chandra R, Burhan E, et al. Effects of introducing Xpert MTB/RIF on diagnosis and treatment of drug-resistant tuberculosis patients in Indonesia: a pre-post intervention study. PLoS One. 2015;10(6):e0123536.
  7. Khann S, Mao ET, Rajendra YP, Satyanarayana S, Nagaraja SB, Kumar AMV. Linkage of presumptive multidrug resistant tuberculosis ( MDR-TB ) patients to diagnostic and treatment services in Cambodia. PLoS One. 2013;8(4):e59903.
  8. Gautam PB, Mishra A, Kumar S. Prevalence of rifampicin resistant mycobacterium tuberculosis and associated factors among presumptive tuberculosis patients in eastern Uttar Pradesh: a cross sectional study. Int J Community Med Public Health. 2018:5(6):2271–6.
  9. Cudahy PGT, Wilson D, Cohen T. Risk factors for recurrent tuberculosis after successful treatment in a high burden setting: a cohort study. BMC Infect Dis. 2020;20(1):789.
  10. Ragonnet R, Trauer JM, Denholm JT, Marais BJ, McBryde ES. High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from? BMC Infect Dis. 2017;17(1):36.
  11. Trinh QM, Nguten HK, Nguyen VN, Nguyen TVA, Sintchenko V, Brais BJ. Tuberculosis and HIV co-infection-focus on the Asia-Pacific region. Int J Infect Dis. 2015;32: 170–8.
  12. Liu Y, Zhang XX, Yu JJ, Liang C, Xing Q, Yao C, et al. Tuberculosis relapse is more common than reinfection in Beijing, China. Infect Dis (Lond). 2020;52(12):858–65.
  13. Najjingo I, Muttamba W, Kirenga BJ, Nalunjogi J, Bakesiima R, Olweny F, et al. Comparison of GeneXpert cycle threshold values with smear microscopy and culture as a measure of mycobacterial burden in five regional referral hospitals of Uganda- A cross-sectional study. PLoS One. 2019;14(5):e0216901.
  14. World Health Organization. Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update. Geneva, Switzerland: WHO; 2017.
  15. Zignol M, van Gemert W, Falzon D, Sismanidis C, Glazio P, Flyod K, et al. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007–2010. Bull World Health Organ. 2012; 90(2):111–9D.
  16. World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children-Policy update. Geneva, Switzerland: WHO Press; 2013.
  17. Soeroto AY, Lestari BW, Santoso P, Chaidir L, Andriyoko B, Alisjahbana B, et al. Evaluation of Xpert MTB-RIF guided diagnosis and treatment of rifampicin-resistant tuberculosis in Indonesia: A retrospective cohort study. PLoS One. 2019;14(2):e0213017.
  18. Nuraeni N, Suryadinata H, Lestari BW. Geographical factors in diagnostic delay among multidrug resistant tuberculosis patients. Althea Med J. 2017;4(3):444–8
  19. Ramadhani AR, Lestari BW, Suryadinata H. Knowledge toward drugs resistant tuberculosis in one of the highest burden drug resistant country. Althea Med J. 2018;5(3):127–32
  20. Htun YM, Khaing TMM, Aung NM, Yin Y, Myint Z, Aung ST, et al. Delay in treatment initiation and treatment outcomes among adult patients with multidrug-resistant tuberculosis at Yangon Regional Tuberculosis Centre, Myanmar: a retrospective study. PLoS One. 2018;13(12): e0209932.
  21. Soeroto AY, Pratiwi C, Santoso P, Lestari BW. Factors affecting outcome of longer regimen multidrug-resistant tuberculosis treatment in West Java Indonesia: a retrospective cohort study. PLoS One. 2021;16(2): e0246284.

DOI: https://doi.org/10.15850/amj.v9n4.2593

Article Metrics

Abstract view : 254 times
PDF - 181 times

 This Journal indexed by




Creative Commons License
AMJ is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License


View My Stats